Loading
A phase 1 trial of MST-0312 run by Mestag Therapeutics Limited, now recruiting.
Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies is a phase 1 interventional study registered as NCT07610941 by Mestag Therapeutics Limited, with 157 participants planned, started 2026-04-09. Conditions recorded: Cancer-Neoplasms. Interventions recorded: MST-0312 and Pembrolizumab.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/